Actively Recruiting
Pregnancy Registry for Women with Migraine Using Erenumab-aooe Tracking Birth Outcomes and Infant Health
Led by Amgen · Updated on 2025-11-04
2842
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the occurrence of major birth defects in babies born to women with migraine who were exposed to erenumab-aooe during pregnancy compared to those not exposed. This observational study also includes pregnant women with migraine who were not exposed to this medication and pregnant women without migraine as comparison groups. The study aims to better understand possible risks of erenumab-aooe exposure during pregnancy using recognized birth defect classification methods. Pregnant women with confirmed migraine who took erenumab-aooe before or during pregnancy form one group, with treatment decisions made by their healthcare providers following local practices. Another group includes pregnant women with migraine who were not exposed to erenumab-aooe, serving as an internal comparison. A third group of pregnant women without migraine acts as an external comparison. Birth defects and other pregnancy outcomes will be tracked and classified using a standard system. Participants will be followed up to 52 weeks after birth to assess the number of infants with major congenital malformations as the main outcome. Additional outcomes include pregnancy complications, rates of miscarriage or preterm birth, infant growth and development issues, and various maternal and fetal health measures. Data will be collected through observation without intervention, with all outcomes monitored over the course of pregnancy and the infants first year.
CONDITIONS
Brief Title
Aimovig Pregnancy Exposure Registry
Research Team
A
Amgen Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here